VYNE Therapeutics (NASDAQ:VYNE) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $5.75 price objective on the stock.

Separately, BTIG Research initiated coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price target on the stock.

VYNE Therapeutics Trading Down 8.9 %

VYNE stock opened at $2.75 on Tuesday. VYNE Therapeutics has a 12-month low of $1.57 and a 12-month high of $4.30. The business’s 50-day moving average is $2.98 and its 200 day moving average is $2.35. The stock has a market cap of $40.57 million, a price-to-earnings ratio of -3.20 and a beta of 1.30.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises about 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.